SOLAR-PROMOTION-GMBH
29.5.2024 14:04:30 CEST | Business Wire | Press release
The German government’s goal is to have an equal share of large-scale power plants and roof-mounted systems. In 2023, the large-scale ground-mounted segment was able to increase by 45 percent. With the adoption of Solar Package I, this segment will continue to grow. The package of measures aims to reduce the red tape associated with solar deployment in order to achieve an annual growth of 22 gigawatt peak from 2026. The latest applications, products and business models for large-scale PV power plants will be on display at Intersolar Europe, the world’s leading exhibition for the solar industry. It will be held in Munich from June 19–21 as part of The smarter E Europe, the continent’s largest alliance of exhibitions for the energy industry. Some 3,000 exhibitors and over 115,000 visitors from all corners of the globe are expected to attend. The event will take place across 19 exhibition halls and an Outdoor Area.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529516051/en/
Intersolar Europe presents innovations in the field of hybrid systems. (© Solar Promotion GmbH)
Hybrid power plants consisting of PV and wind power or storage, or both, offer various benefits: Sun and wind complement each other’s generation profiles and can be combined in a system, making optimal use of energy infrastructure such as interconnection points and the space required to implement the system. The combination with energy storage comes with additional advantages: It can smooth out the volatility of renewables, and the stored electricity can be fed into the grid when it is needed – or it can be traded for a profit. Energy arbitrage enables the targeted provision and marketing of solar and wind energy on the energy exchange. The electricity is stored when the price is low or a lot of renewable electricity is being produced. When it is profitable to sell the stored electricity, it is fed into the grid.
The latest technologies in operation and maintenance
Artificial intelligence (AI) is all the rage right now. It is also increasingly being used in the solar industry, especially in operations and maintenance (O&M). The AI-driven detection and analysis of incidents and deviations in operations and the standardized creation and selection of tickets are processes in which AI can be used to quickly process large amounts of data. In O&M, AI helps free up human resources for more complex tasks and standardize operations. What’s more, AI-supported software solutions can process weather data and create generation forecasts.
Special solar systems: parking lot PV, agricultural PV and floating PV
With Solar Package I, the “special solar systems” defined in the German Renewable Energy Sources Act EEG now have their own tender segment. These applications are becoming more prevalent and dual land use concepts are coming to the forefront of solar deployment plans. The maximum value for tenders has been raised to 9.5 cents/kWh. The products in this segment are rapidly evolving: carport substructures, elevated vertical and horizontal solar technology with and without trackers for agricultural PV, and mounting solutions for floating PV.
Intersolar Europe
As the world’s leading exhibition for the solar industry, Intersolar Europe demonstrates the enormous vitality of the solar market. For more than 30 years, it has been providing a networking opportunity for key players, focusing on the latest trends, developments and business models under the motto “Connecting Solar Business”. Intersolar Europe will take place from June 19–21, 2024 as part of The smarter E Europe at Messe München.
For more information, please visit: www.intersolar.de.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529516051/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom